PRKDC and medullary thyroid gland carcinoma: In order to demonstrate that activated DNA-PKcs is in fact a legitimate drug target we validated our results in human TT cells and probed tissue microarrays of medullary thyroid cancer for the presence of DNA-PKcs phosphorylated at s2056.